Nymox Pharmaceuticals (NASDAQ: NYMX) tanked in pre-market trading at the time of writing on Thursday after the company received a potential Nasdaq delisting notice. According to the company’s press release, the notice stated that “Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company’s shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market.”
The deadline to comply with the NASDAQ listing requirements was July 3.
NYMX stock has tanked by more than 25% year-to-date.
